ICLR - ICON Public Limited Company

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
141.02
+0.38 (+0.27%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close140.64
Open141.61
Bid127.02 x 800
Ask180.00 x 800
Day's Range140.25 - 142.24
52 Week Range118.10 - 165.14
Volume295,280
Avg. Volume227,598
Market Cap7.626B
Beta (3Y Monthly)0.61
PE Ratio (TTM)21.80
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • Business Wire

    ICON plc to Present at Baird's 2019 Global Healthcare Conference

    ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Dr. Steve Cutler, CEO and Mr. Brendan Brennan, CFO of ICON plc, will present at Baird’s 2019 Global Healthcare Conference on Thursday, September 5, 2019. ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies.

  • Business Wire

    ICON and DIA Driving Insights to Action with DIA Live 2019

    ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that it will present DIA Live – a social media aggregation site that allows visitors to track and analyse Twitter conversations from delegates at the DIA Global Annual Meeting (23 - 27 June, San Diego, CA).

  • Business Wire

    ICON’s Acquisition of MeDiNova Research

    ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has acquired a majority shareholding in MeDiNova Research, a site network with research sites in key markets in Europe and Africa, and that it has the right to acquire the remaining shares in the company by Quarter 3 2020. The acquisition further enhances ICON’s patient recruitment capabilities in EMEA and complements ICON’s existing site network in the US, PMG Research.

  • Business Wire

    ICON Awarded Clinical Research Team of the Year and Best in Health Economics and Outcomes Research

    ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has been awarded the Clinical Research Team of the Year (with Eli Lilly and Company), for the second consecutive year, and Best in Health Economics and Outcomes Research (with Bristol-Myers Squibb and LATITUDE, powered by AXON). The awards indicated are ICON’s third win for Clinical Research Team of the Year since the inaugural CARE Awards in 2016, and first win in the Best Health Economics and Outcomes Research category. ICON and Eli Lilly and Company won the award for the successful execution of a full-service Cardiovascular Outcomes Trial (CVOT), in which they were able to achieve exceptional patient retention despite early challenges.

  • ICON Launches New Patient Engagement Platform to Support Improved Patient Experience and Enrollment in Clinical Trials
    Business Wire

    ICON Launches New Patient Engagement Platform to Support Improved Patient Experience and Enrollment in Clinical Trials

    ICON plc, (ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced the release of its web based patient engagement platform, to provide patients with study specific information and connectivity with the nearest investigative site. The solution supplements patient recruitment outreach by sites and increases visibility of potential study participants for sponsors and sites. Patient recruitment specialists work with sponsors to develop outreach programs that incorporate the right mix of digital channels, traditional methods and patient advocacy partnerships to attract patients to a study branded website hosted on the platform.

  • Business Wire

    ICON Wins Multiple Categories in 2019 CRO Leadership Awards

    ICON plc, (ICLR) a global provider of drug development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, has won awards across several categories in the annual CRO Leadership Awards. ICON received 2019 CRO Leadership Awards in five categories, each further divided into three groups – Big Pharma, Small Pharma, and Overall.

  • GlobeNewswire

    Report: Developing Opportunities within Amazon, Prospect Capital, Alliance Data, Duke Realty, Stellus Capital Investment, and ICON — Future Expectations, Projections Moving into 2019

    NEW YORK, Feb. 27, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire

    MolecularMD is acquired by ICON

    PORTLAND, Ore. and CAMBRIDGE, Mass., Feb. 21, 2019 -- MolecularMD Corporation, a  molecular diagnostic specialty laboratory that enables the development and commercialisation.

  • Business Wire

    ICON Launches New Drug Safety Reporting Solution that Ensures Compliance through Automation

    ICON plc, (ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced the release of a new drug safety reporting solution based on an innovative cloud-based system, featuring automated and configurable business rules. The solution ensures compliance in an increasingly complex regulatory environment and enables the sponsor to gain visibility into the safety profile of an investigational product throughout its lifecycle. Using regulatory intelligence from 80 countries, the system is configured with date-stamped decision rules.

  • Business Wire

    ICON Issues Financial Guidance for Full Year 2019

    ICON plc (ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced its financial guidance for the year ended December 31, 2019. For the full year 2019 revenue is expected to be in the range of $2,735 - $2,835 million, representing growth of 5.2 – 9.0% and earnings per share is expected to be in the range of $6.69 - $6.89, representing growth of 10.6 – 13.9%.